GlassScriptPhysician profile
Sean S To
NPI 1922163310
$7,413.48
in general payments reported to CMS, 2019-2025
38 companies · $913 in 2025
The $913 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,243 · 2020: $666 · 2021: $990 · 2022: $941 · 2023: $1,368 · 2024: $1,292 · 2025: $913.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,573.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,573.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,235.32 | 2021-2025 | Arexvy, Trelegy Ellipta |
| Pfizer INC. | $808.07 | 2019-2025 | |
| Abbvie INC. | $705.61 | 2019-2025 | Qulipta, Ubrelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $688.28 | 2019-2025 | Jardiance, Stiolto Respimat |
| Astrazeneca Pharmaceuticals LP | $506.06 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Arbor Pharmaceuticals, INC. | $438.77 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $322.12 | 2019-2024 | Xarelto |
| Abbott Laboratories | $310.71 | 2021-2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $264.56 | 2020-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $236.50 | 2019-2025 | Capvaxive, Gardasil 9, M-M-R II |
| Sanofi-Aventis U.S. LLC | $192.62 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $173.69 | 2019-2020 | |
| Lilly USA, LLC | $166.16 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Allergan, INC. | $159.41 | 2019-2020 | |
| Novo Nordisk INC | $148.87 | 2019-2025 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $146.53 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $119.63 | 2019-2024 | Veozah |
| Shield Therapeutics INC | $79.47 | 2023-2025 | Accrufer |
| Biohaven Pharmaceuticals, INC. | $78.13 | 2021 | |
| Eisai INC. | $57.09 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $55.53 | 2019 | |
| Medtronic, INC. | $52.50 | 2025 | Symplicity G3 |
| Biohaven Pharmaceutical Holding Company LTD. | $49.58 | 2022 | |
| Ardelyx, INC. | $46.09 | 2025 | Ibsrela |
| Edwards Lifesciences Corporation | $43.05 | 2023-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Amgen INC. | $42.41 | 2024 | Otezla, Repatha |
| Dexcom, INC. | $40.34 | 2024 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $34.99 | 2020 | |
| Axsome Therapeutics, INC. | $32.65 | 2025 | Symbravo |
| Abiomed | $31.63 | 2024 | Impella |
| Xeris Pharmaceuticals, INC. | $22.71 | 2024 | Gvoke Hypopen |
| Lucid Diagnostics INC. | $21.48 | 2025 | |
| Bausch Health US, LLC | $21.10 | 2021 | |
| Lifescan, INC. | $18.99 | 2022 | |
| Idorsia Pharmaceuticals US INC | $16.61 | 2023 | Quviviq |
| Acerus Pharmaceuticals Corporation | $16.52 | 2022 | |
| Azurity Pharmaceuticals, INC. | $16.14 | 2023 | Horizant |
| Cequr Corporation | $13.56 | 2024 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean To listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.